May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Olopatadine 0.2% Reduces the Primary Sign and Symptom of Allergic Conjunctivitis During Peak Pollen Periods
Author Affiliations & Notes
  • J.V. Greiner
    Department of Ophthalmology, Schepens Eye Research Inst, Harvard Medical School, Boston, MA
  • M.B. Abelson
    Department of Ophthalmology, Schepens Eye Research Inst, Harvard Medical School, Boston, MA
    Ophthalmic Research Associates, Inc., North Andover, MA Ophthalmic Research Associates, Inc., North Andover, MA
  • P.J. Gomes
    Ophthalmic Research Associates, Inc., North Andover, MA Ophthalmic Research Associates, Inc., North Andover, MA
    Allergy Department,
  • C.T. Vogelson
    Alcon Research, Ltd, Fort Worth, TX
  • T.A. Pasquine
    Alcon Research, Ltd, Forth Worth, TX
  • R.D. Gross
    Department of Ophthalmology, University of Texas, Southwestern Medical Center, Dallas, TX
  • F.D. Turner
    Alcon Research, Ltd, Forth Worth, TX
  • M.V. W. Bergamini
    Alcon Research, Ltd, Fort Worth, TX
  • S.M. Robertson
    Alcon Research, Ltd, Fort Worth, TX
  • Olopatadine 0. 2% Environmental Study Group
    Department of Ophthalmology, Schepens Eye Research Inst, Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships  J.V. Greiner, Alcon R; M.B. Abelson, Alcon F, C; P.J. Gomes, None; C.T. Vogelson, Alcon E; T.A. Pasquine, Alcon E; R.D. Gross, Alcon C, R; F.D. Turner, Alcon E; M.V.W. Bergamini, Alcon E; S.M. Robertson, Alcon E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4854. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.V. Greiner, M.B. Abelson, P.J. Gomes, C.T. Vogelson, T.A. Pasquine, R.D. Gross, F.D. Turner, M.V. W. Bergamini, S.M. Robertson, Olopatadine 0. 2% Environmental Study Group; Olopatadine 0.2% Reduces the Primary Sign and Symptom of Allergic Conjunctivitis During Peak Pollen Periods . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4854.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: A formulation of olopatadine hydrochloride ophthalmic solution (Olopatadine 0.2%) was evaluated in a hybrid environmental study to determine efficacy and safety in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis. Methods: In a double–masked, randomized, placebo–controlled study involving 260 allergic patients, either Olopatadine 0.2% or placebo was instilled by patients into both eyes, once daily for 10 weeks. Throughout the study, patients assessed the daily severity of ocular signs and symptoms. Grass pollen counts were obtained daily from each investigative center. To compare treatment groups, a two–sample t–test was performed on the average diary itching and redness scores for any 14 days, for 14 consecutive days, and for two, non–overlapping 7 consecutive days of highest mean pollen counts at each investigative center. Results: Olopatadine 0.2% is statistically superior to placebo for both itching and redness for any 14 days (p = 0.0039 and p = 0.0117, respectively), for 14 consecutive days (p = 0.0023 and p = 0.0064, respectively), and for two non–overlapping 7 consecutive days (p = 0.0022 and p = 0.0129, respectively) with the highest mean pollen counts by investigator. In addition, the difference between Olopatadine 0.2% and placebo for both itching and redness is statistically significant for 57 of the 70 study days; Olopatadine 0.2% is favored numerically on 69 days for itching and on all 70 days for redness. No patient discontinued from the study due to a treatment–related adverse event, and no patient suffered a serious adverse event related to therapy. Conclusions: Olopatadine 0.2% ophthalmic solution is safe, well tolerated, and effective when dosed once daily for the treatment of the ocular signs and symptoms of allergic conjunctivitis.

Keywords: conjunctivitis • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×